Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
L3Harris
LHX
$53.7B
| $27.2M | 0.03% |
249,359
+200,600
| +411% | +$22.1M |
|
677
Cincinnati Financial
CINF
$26.5B
| $27.2M | 0.03% |
375,000
+203,055
| +118% | +$14.4M |
|
|
LTM
678
DELISTED
LATAM Airlines Group S.A American Depositary Shares (Each representing 1 Common Share)
LTM
| $27.1M | 0.03% |
2,448,995
+673,500
| +38% | +$8.12M |
|
679
Reliance Steel & Aluminium
RS
$21.7B
| $27.1M | 0.03% |
372,112
+229,900
| +162% | +$17.2M |
|
680
Southwest Gas
SWX
$6.67B
| $27.1M | 0.03% |
370,700
+285,800
| +337% | +$22.9M |
|
681
Aptiv
APTV
$10.2B
| $27M | 0.03% |
+308,500
| New | +$25.7M |
|
682
Globe Life
GL
$14B
| $27M | 0.03% |
+352,900
| New | +$26.8M |
|
|
RGC
683
DELISTED
Regal Entertainment Group
RGC
| $27M | 0.03% |
1,317,900
-150,900
| -10% | -$3.2M |
|
|
UNIT
684
Uniti Group
UNIT
$2.38B
| $27M | 0.03% |
1,072,200
-131,900
| -11% | -$3.42M |
|
685
Ternium
TX
$10.7B
| $26.9M | 0.03% |
958,800
-78,200
| -8% | -$2M |
|
686
Bunge Global
BG
$21.7B
| $26.9M | 0.03% |
360,300
-571,200
| -61% | -$43.5M |
|
|
CYOU
687
DELISTED
Changyou.com Limited American Depositary Share
CYOU
| $26.7M | 0.03% |
689,800
+56,500
| +9% | +$1.94M |
|
688
First Horizon
FHN
$12.3B
| $26.6M | 0.03% |
1,527,381
-178,363
| -10% | -$3.17M |
|
689
Lindsay Corp
LNN
$1.17B
| $26.6M | 0.03% |
298,000
+7,900
| +3% | +$680K |
|
|
CALD
690
DELISTED
Callidus Software, Inc.
CALD
| $26.6M | 0.03% |
1,098,701
-262,291
| -19% | -$5.68M |
|
691
Glaukos
GKOS
$11.2B
| $26.6M | 0.03% |
640,700
-565,500
| -47% | -$24.4M |
|
692
SiriusXM
SIRI
$9.43B
| $26.5M | 0.03% |
484,580
-2,110,010
| -81% | -$108M |
|
693
MSC Industrial Direct
MSM
$6.77B
| $26.5M | 0.03% |
308,100
-238,900
| -44% | -$21M |
|
694
lululemon athletica
LULU
$13.6B
| $26.5M | 0.03% |
443,700
-753,400
| -63% | -$39.2M |
|
|
GHDX
695
DELISTED
Genomic Health, Inc.
GHDX
| $26.5M | 0.03% |
813,300
+80,100
| +11% | +$2.54M |
|
|
PDLI
696
DELISTED
PDL BioPharma, Inc.
PDLI
| $26.4M | 0.03% |
10,704,400
-1,332,354
| -11% | -$3.06M |
|
|
NSA
697
DELISTED
National Storage Affiliates Trust
NSA
| $26.4M | 0.03% |
1,143,600
+396,500
| +53% | +$9.51M |
|
698
Fastenal
FAST
$58.9B
| $26.4M | 0.03% |
2,426,176
+1,075,200
| +80% | +$12.1M |
|
699
BJ's Restaurants
BJRI
$1.42B
| $26.4M | 0.03% |
707,500
-89,900
| -11% | -$3.82M |
|
|
ISCA
700
DELISTED
International Speedway Corp
ISCA
| $26.2M | 0.03% |
697,491
+120,025
| +21% | +$4.4M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.